HomeCompareEKGGF vs ARCC

EKGGF vs ARCC: Dividend Comparison 2026

EKGGF yields 43478.26% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EKGGF wins by $1.1890295911865906e+23M in total portfolio value
10 years
EKGGF
EKGGF
● Live price
43478.26%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.1890295911865906e+23M
Annual income
$118,367,411,904,190,840,000,000,000,000.00
Full EKGGF calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — EKGGF vs ARCC

📍 EKGGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEKGGFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EKGGF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EKGGF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EKGGF
Annual income on $10K today (after 15% tax)
$3,695,652.17/yr
After 10yr DRIP, annual income (after tax)
$100,612,300,118,562,220,000,000,000,000.00/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, EKGGF beats the other by $100,612,300,118,562,220,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EKGGF + ARCC for your $10,000?

EKGGF: 50%ARCC: 50%
100% ARCC50/50100% EKGGF
Portfolio after 10yr
$5.945147955932953e+22M
Annual income
$59,183,705,952,095,420,000,000,000,000.00/yr
Blended yield
99.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

EKGGF
No analyst data
Altman Z
-198.7
Piotroski
1/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EKGGF buys
0
ARCC buys
0
No recent congressional trades found for EKGGF or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEKGGFARCC
Forward yield43478.26%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$1.1890295911865906e+23M$24.5K
Annual income after 10y$118,367,411,904,190,840,000,000,000,000.00$1.16
Total dividends collected$1.1886778493816057e+23M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: EKGGF vs ARCC ($10,000, DRIP)

YearEKGGF PortfolioEKGGF Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$4,358,526$4,347,826.09$11,381$541.15+$4.35MEKGGF
2$1,775,702,260$1,771,038,637.53$12,621$284.08+$1775.69MEKGGF
3$676,233,533,658$674,333,532,239.80$13,827$145.31+$676233.52MEKGGF
4$240,727,047,188,757$240,003,477,307,741.90$15,062$73.43+$240727047.17MEKGGF
5$80,105,191,727,727,180$79,847,613,787,235,220.00$16,364$36.89+$80105191727.71MEKGGF
6$24,917,840,645,043,868,000$24,832,128,089,895,195,000.00$17,757$18.49+$24917840645043.85MEKGGF
7$7,245,709,632,152,810,000,000$7,219,047,542,662,613,000,000.00$19,258$9.25+$7245709632152810.00MEKGGF
8$1,969,606,736,781,993,500,000,000$1,961,853,827,475,589,700,000,000.00$20,880$4.63+$1969606736781993472.00MEKGGF
9$500,511,415,390,858,850,000,000,000$498,403,936,182,502,200,000,000,000.00$22,636$2.32+$500511415390858838016.00MEKGGF
10$118,902,959,118,659,060,000,000,000,000$118,367,411,904,190,840,000,000,000,000.00$24,539$1.16+$1.1890295911865906e+23MEKGGF

EKGGF vs ARCC: Complete Analysis 2026

EKGGFStock

CardioComm Solutions, Inc. develops advanced software and hardware products, and core laboratory reading services related to electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems for medical and consumer markets worldwide. The company's technology is used in a range of products for the recording, transmission, viewing, analyzing, reporting, and storage of ECGs for arrhythmia screening, diagnosis, and management of cardiac patients. Its proprietary device connectivity and ECG management technologies are used in medical, consumer, clinical research, and telemedicine solutions. The company's software products include Global ECG Management System (GEMS), a software solution for cardiac event monitoring; GlobalCardio 12 Lead, a web enabled ECG device that is EMR compatible; and GEMS Lite for Windows, an electronic ECG receiving system. It also offers software modules, such as GEMS WIN Air, a live wireless ECG monitoring solution; AutoAttendant, which allows healthcare providers to focus on providing patient care; GEMS HL7 Interface that allows patient and follow-up information to be sent in an HL7 message format to other EMR systems that are HL7 compliant; and GlobalCardio EMR integration that enables bidirectional movement of data, including patient information, reports, and links. In addition, the company provides hardware products comprising HeartCheck PEN and HeartCheck, which are handheld ECG monitors; and Sirona telephonic and wireless event recorders, as well as HeartCheck CardiBeat. Further, it offers ASP services, including C4 ECG management services; and HeartCheck SMART Monitoring. Additionally, the company provides other products comprising GlobalCardio 3 Lead; ECG Viewer SDK; QRS Diagnostic; and QRS 12 Lead Universal products. CardioComm Solutions, Inc. was incorporated in 1989 and is headquartered in Toronto, Canada.

Full EKGGF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this EKGGF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EKGGF vs SCHDEKGGF vs JEPIEKGGF vs OEKGGF vs KOEKGGF vs MAINEKGGF vs HTGCEKGGF vs GBDCEKGGF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.